Axon Enterprise, Inc.

The forensic scores point in different directions, and a careful reader should weigh them together. The Beneish M-Score is -2.620, which is below the -1.78 threshold and therefore not in the elevated manipulation-risk zone; this is a screening output, not proof that the reported figures are accurate. The Altman Z″-Score of 3.38 falls in the safe zone, a model designed to flag financial distress rather than to measure profitability. The Piotroski F-Score is 6 of 8 computable signals, meaning six of the eight available checks on profitability, leverage, and efficiency were favorable. The Fog Index of 19.45 is above 18, the band the label describes as very hard to read, so the MD&A requires extra effort. Operating cash flow of $211.34 million was 1.70 times net income of $124.66 million in 2025, which supports the cash backing of reported earnings even as earnings fell. The 10-K names competitors including Motorola Solutions, Flock Safety, and Genetec across these product lines. The 10-Q shows a $300.0 million line of credit with $290.9 million available and no borrowings at June 30, 2026, but the provided data does not show what the $1.73 billion of 2025 long-term debt consists of, so readers may want to look at the debt footnotes in the 10-K. Liabilities of $3.76 billion compare with equity of $3.24 billion at year-end 2025. Directors and officers also adopted or terminated Rule 10b5-1 trading plans during the quarter, with maximum share amounts of 135,466, 100,390, 15,839, and 10,337 shares, excluding tax withholding. Readers may want to look at those plans alongside the rest of the filing. Overall, the filings show strong top-line growth and cash generation alongside a sharp 2025 drop in profit and a large increase in debt, which warrants a close read.

Catalyst.Revenue rose 33.5% year over year to $2.78 billion for 2025, up from $2.08 billion in 2024. The MD&A excerpt provided is limited to critical estimates, market risk, and controls, so it does not explain the growth drivers. The risk-factor text names the product lines the company competes in: Axon Evidence for digital evidence management, Axon Fusus for real-time crime centers, Draft One for AI report drafting, Axon Air for drone software, Sky-Hero for indoor tactical drones, and VR de-escalation training. It also describes the Carbyne acquisition, which extends the company's emergency communications offerings into the NG911 call-handling layer.

Hidden risk.Revenue grew while profit fell sharply. Net income dropped from $377.03 million in 2024 to $124.66 million in 2025, and the company recorded an operating loss of $62.08 million in 2025 compared with operating income of $58.54 million in 2024. Operating cash flow also fell, from $408.31 million to $211.34 million. Long-term debt was $0 at the end of 2024 and $1.73 billion at the end of 2025. The 10-K disclosed a material weakness in revenue recognition, which the 10-Q says was remediated as of June 30, 2026.